# LDV Blog

DANNCE.AI is bringing to market a novel phenotyping platform to digitize the clinical assessments used by clinicians and drug developers to quantify movement. We led their $2.6M pre-seed round along with co-investors Glasswing Ventures, The Leo Lion Company, Duke Capital Partners, and Merck Digital Sciences Studio.

[Read More](/content/blog/ai-in-neuroscience-partnering-with-dannceai-to-increase-drug-efficacy-improve-the-lives-of-people-with-movement-disorders/index.html)